<DOC>
	<DOCNO>NCT01063556</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics donepezil HCl 3 mg subject end-state renal disease receive haemodialysis .</brief_summary>
	<brief_title>Pharmacokinetics Study Donepezil HCl Subjects Receiving Haemodialysis .</brief_title>
	<detailed_description>This randomise , single-center , open-label , single-dose , two-period crossover pharmacokinetics study donepezil HCl tablet 3 mg subject receive haemodialysis . Subjects receive haemodialysis . After interval 15 day , subject receive treatment .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : Subjects endstage renal disease receive haemodialysis . Subject able willing give write informed consent . Exclusion criterion : Subjects know hypersensitivity drug food . Subjects correct QT interval great 450 msec Screening period .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>end-stage renal disease hemodialysis donepezil hydrochloride pharmacokinetics Cross-Over Study</keyword>
</DOC>